Uncategorized | Atrino Health

id: 80d4cf12-08b8-43f7-8919-a0cebfed6d15ind_id_onekey: trust_level: 0onekey_id: first_name: first_name_transliterated: last_name: last_name_transliterated: middle_name: middle_name_transliterated: suffix_name: activity_phone: intl_phone: local_phone: intl_fax: title:...

Sign-Up Data

by thanh-tam nguyen | May 16, 2023 | Uncategorized

user_id: 80d4cf12-08b8-43f7-8919-a0cebfed6d15userId: 80d4cf12-08b8-43f7-8919-a0cebfed6d15trust_level: 2first_name: ABDALLAHlast_name: NAILIemail: ABDALLAH.NAILI@yopmail.comphone: country: postal_code: city: professional_type: TYP.Pprofessional_type_label: speciality:...

European Commission approves Cabometyx in combination with Opdivo as a first-line treatment for patients living with advanced renal cell carcinoma

by Mathieu | Oct 18, 2022 | Uncategorized

Approval based on pivotal Phase III CheckMate -9ER trial data, also recently published in the New England Journal of Medicine1 Trial data showed Cabometyx® (cabozantinib) in combination with Opdivo® (nivolumab) doubled median progression-free survival...

ARTICLE 5

by Mathieu | Feb 20, 2017 | Uncategorized

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Ut velit mauris, egestas sed, gravida...

« Older Entries

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Performance

Analytics

Others

HealthCare Locator

User Information

OneKey Data

Sign-Up Data

European Commission approves Cabometyx in combination with Opdivo as a first-line treatment for patients living with advanced renal cell carcinoma

ARTICLE 5

Recent Posts

Recent Comments